Trials / Completed
CompletedNCT00703898
Durability of Nevirapine-Based Antiretroviral Regimen
Durability of Stavudine, Lamivudine and Nevirapine Among Advanced HIV-1 Infected Patients With/Without Prior Co-Administration of Rifampicin: A 144-Week Prospective Study
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 140 (actual)
- Sponsor
- Bamrasnaradura Infectious Diseases Institute · Other Government
- Sex
- All
- Age
- 15 Years
- Healthy volunteers
- Not accepted
Summary
Although nevirapine is used as an alternative to efavirenz for initial regimen in developed countries, nevirapine has still been a key antiretroviral drug in many resource-limited countries including Thailand due to its accessibility and affordability. In addition, a component of stavudine and lamivudine is still widely used as a backbone in the antiretroviral regimen in this setting.To date, data on the durability of a regimen of stavudine, lamivudine and nevirapine are very limited, particularly from the resource-limited settings.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nevirapine | 200 mg/day twice a day |
Timeline
- Start date
- 2004-11-01
- Primary completion
- 2009-12-01
- Completion
- 2010-04-01
- First posted
- 2008-06-24
- Last updated
- 2008-07-08
Locations
1 site across 1 country: Thailand
Source: ClinicalTrials.gov record NCT00703898. Inclusion in this directory is not an endorsement.